Wolf, J. M.; Gubert Borges, B.; Pereira Fagundes, P.; de Souza, V.; Brenner, A.; Petek, H.; Michelon dos Santos, W.; Gasparetto Maccari, J.; Rohsig, V.; Parrini Mutlaq, M.; Nasi, L. A. Adverse Drug Events, Comorbidities, and Older Age Are Statistically More Prevalent in COVID-19 Hospitalized Patients Treated With Remdesivir Than Tocilizumab in a Private Hospital from Southern Brazil. Clin Biomed Res 2023, 43.